ATE525649T1 - Nachweis von proteinen mit veränderter konformation - Google Patents

Nachweis von proteinen mit veränderter konformation

Info

Publication number
ATE525649T1
ATE525649T1 AT04812753T AT04812753T ATE525649T1 AT E525649 T1 ATE525649 T1 AT E525649T1 AT 04812753 T AT04812753 T AT 04812753T AT 04812753 T AT04812753 T AT 04812753T AT E525649 T1 ATE525649 T1 AT E525649T1
Authority
AT
Austria
Prior art keywords
proteins
detection
altered conformation
prions
conformation
Prior art date
Application number
AT04812753T
Other languages
English (en)
Inventor
Cindy Orser
Anne Grosset
Eugene Davidson
Original Assignee
Adlyfe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlyfe Inc filed Critical Adlyfe Inc
Application granted granted Critical
Publication of ATE525649T1 publication Critical patent/ATE525649T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT04812753T 2003-12-04 2004-12-03 Nachweis von proteinen mit veränderter konformation ATE525649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/728,246 US20050026165A1 (en) 2001-05-31 2003-12-04 Detection of conformationally altered proteins and prions
PCT/US2004/040309 WO2005057166A2 (en) 2003-12-04 2004-12-03 Detection of conformationally altered proteins and prions

Publications (1)

Publication Number Publication Date
ATE525649T1 true ATE525649T1 (de) 2011-10-15

Family

ID=34677130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812753T ATE525649T1 (de) 2003-12-04 2004-12-03 Nachweis von proteinen mit veränderter konformation

Country Status (7)

Country Link
US (3) US20050026165A1 (de)
EP (2) EP1700096B1 (de)
JP (1) JP4815355B2 (de)
AT (1) ATE525649T1 (de)
AU (2) AU2004297579B2 (de)
CA (1) CA2548812A1 (de)
WO (1) WO2005057166A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
AU2002320045B2 (en) * 2001-05-31 2008-05-08 Adlyfe, Inc. Misfolded protein sensor method
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
EP1853915B1 (de) * 2005-02-15 2011-10-12 Adlyfe, Inc. Verfahren zum nachweis falsch gefalteter proteine und prionen
WO2007030804A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Prion-specific peptoid reagents
WO2007047815A2 (en) * 2005-10-18 2007-04-26 The Brigham And Women's Hospital, Inc. Diagnosis of transmissible spongiform encephalopathy
EP2345417A1 (de) 2005-12-22 2011-07-20 Vib Vzw Mittel und Verfahren zur Interferenz mit Proteinen
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
JP5097206B2 (ja) * 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
CN101772512A (zh) * 2007-06-04 2010-07-07 弗拉芒区生物技术研究所 用交叉β结构靶向诱导蛋白质聚集
AU2009226161A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
JP2011520108A (ja) * 2008-04-30 2011-07-14 ノバルティス アーゲー 病原性配座異性体についてのアッセイ
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CN102365295A (zh) * 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
WO2011056958A2 (en) * 2009-11-06 2011-05-12 Adlyfe, Inc. Detection and treatment of traumatic brain injury
EP2712425A2 (de) 2011-04-27 2014-04-02 Adlyfe, Inc. Visueller nachweis von amyloidproteinen
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
GB201411616D0 (en) * 2014-06-30 2014-08-13 Cambridge Entpr Ltd Diagnosis and treatment of neurodegenerative disorders
CN107406513B (zh) 2014-07-25 2022-07-29 台湾地区“中央研究院” 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
CN104215777B (zh) * 2014-09-18 2016-01-20 首都医科大学宣武医院 一种检测血红蛋白结合磷酸化alpha-突触核蛋白的方法
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
EP3621979A1 (de) 2017-05-09 2020-03-18 VIB vzw Mittel und verfahren zur behandlung von bakteriellen infektionen

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
WO1993011155A1 (en) * 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments of prion proteins
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5578639A (en) * 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
EP1416280A3 (de) * 1995-09-14 2005-08-10 The Regents of the University of California Antikörper spezifisch für natives PrPsc
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
ATE249046T1 (de) * 1996-05-14 2003-09-15 Winnacker Ernst Ludwig Prof Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US20010001061A1 (en) * 1997-02-21 2001-05-10 Prusiner Stanley B. Assay for disease related conformation of a protein
JP2001515044A (ja) * 1997-08-14 2001-09-18 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 蛍光アミロイドＡβペプチドとその使用
DE59805338D1 (de) * 1997-09-19 2002-10-02 Evotec Ag Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen
WO2000006990A2 (en) * 1998-07-27 2000-02-10 Ljl Biosystems, Inc. Apparatus and methods for time-resolved spectroscopic measurements
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
US6214565B1 (en) * 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
US6750025B1 (en) * 1998-07-09 2004-06-15 V.I. Technologies, Inc. Method of detecting and isolating prion protein and variants thereof
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
AU765753B2 (en) * 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
BR0012765A (pt) 1999-07-27 2002-04-02 Imp College Innovations Ltd Peptìdeo, métodos de fabricar um anticorpo, de fabricar um agente de ligação capaz de ligar-se a uma forma celular de uma proteìna de prion, de remover uma forma celular de uma proteìna de prion de uma amostra, e de usar um anticorpo e/ou agente de ligação, anticorpo, agente de ligação, uso de um anticorpo ou agente de ligação, kit, e , sequência de peptìdeo de uma forma celular de uma proteìna de prion
GB9917724D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
EP1210360A4 (de) 1999-08-23 2005-03-02 Univ California Verbindungen, die beta-strränge von peptiden nachahmen
DE19952955A1 (de) * 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Charakterisierung und zur Auftrennung von molekularen Assoziaten
US6399314B1 (en) * 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
CA2405568A1 (en) 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
RS51523B (sr) * 2000-07-07 2011-06-30 Laboratoires Serono Sa. Rana dijagnoza konformacionih bolesti
US6780641B2 (en) * 2000-07-10 2004-08-24 University Of British Columbia Immortalized human microglia cell line
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US7303907B2 (en) * 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
AR035956A1 (es) 2001-04-17 2004-07-28 Femtolink Biotechnologies Llc Deteccion y cuantificacion de isoformas de prion en enfermedades neurodegenerativas mediante espectrometria de masas.
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
AU2002320045B2 (en) * 2001-05-31 2008-05-08 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
EP1421198A4 (de) * 2001-06-26 2006-08-30 New York State Office Of Menta Screeningmethoden mit hohem durchsatz auf zellbasis
CA2467914A1 (en) * 2001-12-10 2003-06-19 Applied Research Systems Ars Holding N.V. Prion inhibiting peptides and derivatives thereof
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
ES2564293T5 (es) * 2002-02-28 2019-04-04 Microsens Biophage Ltd Enlazamiento de formas patológicas de proteínas priónicas
DE60325519D1 (de) * 2002-03-01 2009-02-12 Hoffmann La Roche Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit
FR2837401B1 (fr) * 2002-03-25 2004-12-03 Commissariat Energie Atomique Procede de concentration de macromolecules ou agglomerats de molecules ou particules
WO2003085086A2 (en) * 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
JP2004155688A (ja) 2002-04-30 2004-06-03 Biofrontier Kenkyusho:Kk シャペロン活性を有する合成ペプチド、脱炭酸活性の測定方法、伝達性海綿状脳症用薬剤及びその探索方法
EP1534746A2 (de) * 2002-08-23 2005-06-01 Copenhagen Biotech Assets APS Mischpeptide zum nachweis und behandlung der von prion-proteinen verursachten krankheiten
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
ES2527408T3 (es) * 2002-12-03 2015-01-23 North Carolina State University Ligandos de proteínas priones y procedimientos de uso
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
WO2005010533A2 (en) * 2003-07-31 2005-02-03 Hadasit Medical Research Services & Development Ltd. Methods and kits for the detection of prion diseases
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
ES2398394T3 (es) * 2003-08-13 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Reactivos peptídicos específicos de prión
JP3910569B2 (ja) * 2003-08-19 2007-04-25 独立行政法人科学技術振興機構 アミロイドβ蛋白質のアミロイド線維化を増幅するための試薬
WO2005111619A1 (en) * 2004-04-29 2005-11-24 Marc Ramael Method and kit for detecting components in a sample
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
EP1853915B1 (de) 2005-02-15 2011-10-12 Adlyfe, Inc. Verfahren zum nachweis falsch gefalteter proteine und prionen
EP1848817B1 (de) * 2005-02-19 2013-04-24 Peoplebio, Inc. Verfahren zum nachweis mit unterscheidung der multimerform von der monomerform von multimerbildenden polypeptiden
JP5097206B2 (ja) 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
US20090274621A1 (en) 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
AU2009226161A1 (en) 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9556247B2 (en) 2010-05-25 2017-01-31 System Of Systems Analytics, Inc. Stabilized amyloid-beta oligomers and uses thereof
EP2712425A2 (de) 2011-04-27 2014-04-02 Adlyfe, Inc. Visueller nachweis von amyloidproteinen

Also Published As

Publication number Publication date
WO2005057166A3 (en) 2006-11-30
AU2010249147A1 (en) 2010-12-23
EP1700096A2 (de) 2006-09-13
EP1700096B1 (de) 2011-09-21
CA2548812A1 (en) 2005-06-23
EP1700096A4 (de) 2007-11-21
WO2005057166A2 (en) 2005-06-23
JP4815355B2 (ja) 2011-11-16
JP2007536502A (ja) 2007-12-13
AU2004297579B2 (en) 2010-09-02
EP2312312A2 (de) 2011-04-20
US20080171341A1 (en) 2008-07-17
US9638702B2 (en) 2017-05-02
US20150233948A1 (en) 2015-08-20
US20050026165A1 (en) 2005-02-03
AU2004297579A1 (en) 2005-06-23
EP2312312B1 (de) 2016-03-02
EP2312312A3 (de) 2011-08-03

Similar Documents

Publication Publication Date Title
EP1700096A4 (de) Nachweis von proteinen und prionen mit veränderter konformation
ATE424560T1 (de) Marker für neuromyelitis optica
EP1623227A4 (de) Proteine, sensoren und verfahren zur charakterisierung von analyten damit
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
DE60328069D1 (de) Test-Photomaske, Streulichtbewertungsverfahren, und Streulichtkompensierungsverfahren
DE602005023260D1 (de) Markierungsreagentien, markierte analyten, einschliesslich mischungen davon, und davon abgeleitete fragmentionen und verfahren zu deren analyse
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
ATE487142T1 (de) Proteinnachweisreagentien und -verfahren mit farbstoffen und dextrinen
DE602004023180D1 (de) Informationsdetektionseinrichtung, -verfahren und -programm
EP2074427A4 (de) Diagnostik-biomolekül(e)
ATE528649T1 (de) Verfahren zum nachweis falsch gefalteter proteine und prionen
EP1788093A4 (de) Gerät, verfahren und kit zum nachweis von bakterien
DE60328055D1 (de) Verfahren zum nachweis von pathogenen mykobakterien in klinischen proben
WO2007089372A3 (en) A position detecting system that self-monitors for connectivity faults
DE602004016599D1 (de) Abweichungsdetektionsvorrichtung und informationsgerät mit verwendung derselben
DK2327792T3 (da) Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
DE602004022472D1 (de) Vorrichtung für Erkennung von Änderungsinformation
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DE60327121D1 (de) Leseverfahren, und Responder und Interrogator

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties